DHR
Danaher Corporation
Diagnostics & Research · Healthcare · United States
236.98
close · 2026-10-29
value
63
cheaper than peers63
quality
56
stronger fundamentals56
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| forward P/E | 25.43× | 78 |
| price to book | 3.11× | 67 |
| EV to EBITDA | 22.57× | 56 |
| price to sales | 6.55× | 40 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 19.8% | 82 |
| return on equity | 7.6% | 60 |
| debt to equity | 53.0% | 53 |
| revenue growth | 5.5% | 24 |
4 of 4 measures available
Facts
| market cap | $167B |
| free cash flow | $4.33B |
| employees | 58,000 |
| first trade | 1978-12-29 |
| next earnings | 2026-10-21 |
| fundamentals updated | 2026-10-21 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 5.05 | 5.29 | 6.38 | 9.66 |
| free cash flow | $5.26B | $5.30B | $5.78B | $7.40B |
| net income | $3.61B | $3.90B | $4.76B | $7.21B |
| revenue | $24.57B | $23.88B | $23.89B | $26.64B |
| unusual items | -$228.0M | -$57.0M | -$182.0M | -$271.0M |